File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41420-020-00369-w
- Scopus: eid_2-s2.0-85096535364
- PMID: 33251029
- WOS: WOS:000592591300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
Title | SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? |
---|---|
Authors | |
Keywords | Cell death Microbiology |
Issue Date | 2020 |
Publisher | Nature Publishing Group: Open Access Journals. The Journal's web site is located at http://www.nature.com/cddiscovery/ |
Citation | Cell Death Discovery, 2020, v. 6, p. article no. 130 How to Cite? |
Abstract | Since the outbreak of the new coronavirus in 2019 (SARS-CoV-2), many studies have been performed to better understand the basic mechanisms and clinical features of the disease. However, uncertainties of the underlying mechanisms of multiple organ involvement remain. A substantial proportion of severe coronavirus disease 2019 (COVID-19) patients have lymphopenia, low serum iron levels, and multiple organ involvement. Several therapeutic agents have been used for different stages of the disease, but the treatment for severe disease is still suboptimal. Understanding the mechanism of programmed cell death in COVID-19 may lead to better therapeutic strategies for these patients. On the basis of observations of basic science studies and clinical researches on COVID-19, we hypothesize that ferroptosis, a novel programmed cell death, may be an important cause of multiple organ involvement in COVID-19 and it might serve as a new treatment target. In spite of the existing findings on the involvement of ferroptosis in SARS-CoV-2 infection, there is no reported study to uncover how does ferroptosis acts in SARS-CoV-2 infection yet. Uncovering the role of ferroptosis in SARS-CoV-2 infection is essential to develop new treatment strategies for COVID-19. Intracellular cell iron depletion or new generation of ferroptosis inhibitors might be potential drug candidates for COVID-19. We hope this hypothesis may launch a new wave of studies to uncover the association of ferroptosis and SARS-CoV-2 infection in vitro and in vivo. |
Persistent Identifier | http://hdl.handle.net/10722/304546 |
ISSN | 2023 Impact Factor: 6.1 2023 SCImago Journal Rankings: 1.668 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | YANG, M | - |
dc.contributor.author | Lai, CL | - |
dc.date.accessioned | 2021-09-23T09:01:35Z | - |
dc.date.available | 2021-09-23T09:01:35Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Cell Death Discovery, 2020, v. 6, p. article no. 130 | - |
dc.identifier.issn | 2058-7716 | - |
dc.identifier.uri | http://hdl.handle.net/10722/304546 | - |
dc.description.abstract | Since the outbreak of the new coronavirus in 2019 (SARS-CoV-2), many studies have been performed to better understand the basic mechanisms and clinical features of the disease. However, uncertainties of the underlying mechanisms of multiple organ involvement remain. A substantial proportion of severe coronavirus disease 2019 (COVID-19) patients have lymphopenia, low serum iron levels, and multiple organ involvement. Several therapeutic agents have been used for different stages of the disease, but the treatment for severe disease is still suboptimal. Understanding the mechanism of programmed cell death in COVID-19 may lead to better therapeutic strategies for these patients. On the basis of observations of basic science studies and clinical researches on COVID-19, we hypothesize that ferroptosis, a novel programmed cell death, may be an important cause of multiple organ involvement in COVID-19 and it might serve as a new treatment target. In spite of the existing findings on the involvement of ferroptosis in SARS-CoV-2 infection, there is no reported study to uncover how does ferroptosis acts in SARS-CoV-2 infection yet. Uncovering the role of ferroptosis in SARS-CoV-2 infection is essential to develop new treatment strategies for COVID-19. Intracellular cell iron depletion or new generation of ferroptosis inhibitors might be potential drug candidates for COVID-19. We hope this hypothesis may launch a new wave of studies to uncover the association of ferroptosis and SARS-CoV-2 infection in vitro and in vivo. | - |
dc.language | eng | - |
dc.publisher | Nature Publishing Group: Open Access Journals. The Journal's web site is located at http://www.nature.com/cddiscovery/ | - |
dc.relation.ispartof | Cell Death Discovery | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Cell death | - |
dc.subject | Microbiology | - |
dc.title | SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? | - |
dc.type | Article | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/s41420-020-00369-w | - |
dc.identifier.pmid | 33251029 | - |
dc.identifier.pmcid | PMC7687212 | - |
dc.identifier.scopus | eid_2-s2.0-85096535364 | - |
dc.identifier.hkuros | 325486 | - |
dc.identifier.volume | 6 | - |
dc.identifier.spage | article no. 130 | - |
dc.identifier.epage | article no. 130 | - |
dc.identifier.isi | WOS:000592591300001 | - |
dc.publisher.place | United Kingdom | - |